Skip to search formSkip to main contentSkip to account menu

Algenpantucel-L

Known as: Alpha (1,3) Galactosyltransferase Tumor Vaccine, Alpha-1,3-Galactosyltransferase-expressing Allogeneic Pancreatic Tumor Cell Vaccine, Alpha-Gal Pancreatic Cancer Vaccine 
A cancer vaccine comprised of irradiated allogeneic pancreatic cancer cells transfected to express murine alpha-1,3-galactosyltransferase with… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

Cancer Vaccines

Narrower (1)

Hyperacute Pancreatic Cancer Vaccine
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Is There Efficacy Beyond Cytotoxic Chemotherapy for Pancreatic Cancer?
Pancreatic ductal adenocarcinoma is the fourth leading cause of cancer death in the United States, and by the year 2020, it is… 
Review
2015
Review
2015
Novel adjuvant therapies for pancreatic adenocarcinoma.
Contemporary adjuvant therapy for pancreatic cancer patients following surgical resection includes chemotherapy and… 
2014
2014
Correlation of anti-calreticulin antibody titers with improved overall survival in a phase 2 clinical trial of algenpantucel-L immunotherapy for patients with resected pancreatic cancer.
3029 Background: Algenpantucel-L immunotherapy consists of allogeneic pancreatic cancer cells that have been genetically modified… 
2012
2012
920 Addition of Algenpantucel-L Immunotherapy to Standard Adjuvant Therapy for Pancreatic Cancer: A Phase 2 Study
2012
2012
Addition of algenpantucel-L immunotherapy to standard of care (SOC) adjuvant therapy for pancreatic cancer.
4049 Background: Resected pancreatic cancer carries a one year survival rate of ~65%. Algenpantucel (HyperAcute-Pancreas, HAPa… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)